The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
This new facility strengthens Latin America as a collaborative hub
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
Subscribe To Our Newsletter & Stay Updated
